Adapt Pharma Acquires Narcan NDA, License to the Narcan Trademark.
M2 EQUITYBITES-July 2, 2015-Adapt Pharma Acquires Narcan NDA, License to the Narcan Trademark
(C)2015 M2 COMMUNICATIONS http://www.m2.com
2 July 2015 - Irish pharmaceutical company Adapt Pharma Ltd. has obtained a license to the Narcan trademark and acquired the related Narcan (naloxone HCl injection) New Drug Application, the company said on Thursday.
Terms of the deal were not disclosed.
Narcan was the first naloxone product approved by the US Food and Drug Administration as a treatment for opioid overdose in 1971. Narcan has not been distributed under the brand name since 2009; however, the Narcan trademark retains very high brand recognition.
Adapt estimates that over the past year, Narcan has been mentioned in media reports and searched on the internet approximately as frequently as naloxone, the generic name for Narcan.
The company said that this high brand recognition is a valuable tool for public health communications, especially given the imperative to build deeper public awareness of treatment options for opioid overdose.
Adapt Pharma previously announced that it had commenced a rolling submission of an NDA to the FDA for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose.
Use of the Narcan name is subject to FDA review and approval.
Adapt Pharma's strategy is to identify, evaluate, selectively acquire and enhance the value of late-stage development, and FDA approved, pharmaceutical products. Adapt Pharma's company headquarters are in Dublin, Ireland, with its US headquarters in Radnor, Pennsylvania.
((Comments on this story may be sent to email@example.com))